Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

Oct 10, 2017

Table of Contents

Novo petitions FDA to require copies of Victoza to conduct clinical trials

With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arguing the manufacturing process for its drug is so complex that equivalence of a copy couldn’t be certain without clinical trials. Actually, the petition, which Novo filed last week, asks the FDA to refrain from approving ANDAs that reference any of its liraglutide-containing drugs, which include Saxenda and Xultophy in addition to Victoza, the dominant GLP-1 in the market with $2.1 billion in U.S. sales last year. While FDA guidance already holds biosimilar manufacturers to a higher manufacturing standard than originators, Novo argues that the “complexity of the recombinant-derived liraglutide product and its efficacy and safety is specifically tied to the manufacturing process.”

J&J invests $350M in EU biologics operation

Johnson & Johnson is making a big investment in its biologics capacity, this month starting a $350 million project to expand a site in Ireland, a move that will add 200 jobs. J&J today confirmed the expansion in which its Janssen drug unit will invest more than €300 million to expand its Ringaskiddy, County Cork facility by 19,100 square meters (205,590 square feet). The project is kicking off this month and is expected to take two years to complete. Janssen says it will add 200 jobs to the site when the new facilities are up and running. In addition to the new manufacturing facility, the project includes expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes.

Downloads

Article in PDF

Recent Articles

‘Killer’ Mosquito to be released in 20 US states to fight mosquitoes

HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams...

Antibody-Drug Conjugate Market Insight

Will Roche’s Crovalimab An Answer to AstraZeneca PNH Treatment Drugs?

U.K. weighs drug rationing; Applying Digital; FDA slaps Florida

Trial failure for Xarelto in clot prevention, Bayer says its won’t affect sales

German pharma giant Bayer announced that it has stopped a trial of Xarelto in the secondary prevention of stroke and embolism for lack of efficacy, but Bayer who markets in partnership with Johnson & Johnson says that the demise of the trial would not affect its sales estimates for Xarelto. The product has formidable rivals in Eliquis from Pfizer and Bristol-Myers Squibb and Boehringer Ingelheim’s Pradaxa, with BI boasting the advantage of having an approved product that can be used alongside it in cases of uncontrolled bleeding. However, one of the reasons Bayer may be so confident about hitting that $5.3 billion peak sales goal for Xarelto is that it did chart one piece of good research news recently. At the European Society of Cardiology meeting in August, Bayer and J&J released data showing that Xarelto paired with aspirin slashed the risk of adverse cardiovascular events in patients with coronary artery disease and/or peripheral artery disease by 24% over aspirin by itself.

Roche’s Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Roche may be able to keep its bladder cancer nod for Tecentriq despite its phase 3 failure to improve overall survival but might not keep its market share. Use of the med in the bladder-cancer space has been declining, with rival Keytruda from Merck “displacing Tecentriq,”, according to a Barclays analyst. Roche’s drug, which was the first immuno-oncology agent of five to win a green light in the field, accounts for the greatest overall share of the bladder-cancer market–and half the immuno-oncology market for the indication. But use has been declining, as it first ran into trouble in May, when it announced that Tecentriq–approved last year on the basis of phase 2 data durable response data–couldn’t significantly top chemo in a phase 3 study. The flop put Tecentriq’s approval in question and raised red flags for fellow PD-1/PD-L1 drugmakers who, aside from Merck, can’t yet boast positive OS data of their own.